Evaluating a Cardiology Quality Program for Heart Failure and Atrial Fibrillation

This observational study is looking at how well a program works that sends quarterly emails to heart doctors about ways to improve care for patients with heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AFib). Researchers want to see if these emails help doctors prescribe the right medications to eligible patients. You might be able to join if you are 18 to 90 years old and have an active diagnosis of atrial fibrillation with a CHADS2VASC score of at least 2 (for males) or 3 (for females), or if you have HFrEF with a recent ejection fraction (EF) of 40% or less. You also need to have had an outpatient cardiology visit in the past three months. The study aims to enroll 7000 participants. The main goal is to measure the percentage of eligible patients who are prescribed these medications, measured on Day 1.

Study design
This is an observational study, meaning researchers will watch and collect information without giving any specific treatments. It plans to include 7000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Day 1, which suggests a short follow-up period for this specific measurement.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07283666

Subspecialty Ambulatory Quality Cardiology Program

Enrolling by Invitation
Not specifiedAges 18–90Observational
NYU Langone Health
~7,000 participants
Updated 2025-12-16 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of patients eligible for medications who are prescribed these medications
Measured over Day 1
Heart Failure With Reduced Ejection Fraction
Atrial Fibrillation

NCT07283666

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • NYU Langone Health

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Amrita Mukhopadhyay, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Active diagnosis of atrial fibrillation
CHADS2VASC of at least 2 in males and at least 3 in females
Outpatient cardiology visit in past 3 months
Most recent EF ≤40
Age 18-90
Outpatient cardiology visit in past 3 months

Exclusion

LAAO device
Hemorrhagic Stroke
SBP\<90
eGFR\<30
Potassium\>5
Active allergy to MRA
Acknowledge reason on heart failure alert
Mechanical circulatory device
Cardiac amyloid diagnosis
  • Percentage of patients eligible for medications who are prescribed these medicationsDay 1